New insights to structure and immunological features of Leishmania lipophosphoglycan3
Maryam Hosseinia a, Mostafa Haji-Fatahalihaa a, Abolfazl Miahipour b, Mehdi Yousefic
a Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
b Department of Medical Parasitology and Mycology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
c Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Leishmaniasis is a major public infectious disease caused by the genus Leishmania. No effective drug or vaccination
strategy for leishmaniasis has been designed yet. Several intracellular Leishmania antigens have been
recognized to serve in vaccination, ensuring long-lasting protection against Leishmania infection.
Lipophosphoglican 3 (LPG3) as a member of the heat shock protein 90 family involves in the synthesis of
lipophosphoglycan (LPG) and implicates in parasite virulence. Regarding the immunological properties of LPG3
particularly its N-terminal fragment, it would be considered as a favourable adjuvant in Leishmania vaccination.